Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooledpost hocanalysis-Reference-Cited by-同舟云学术

Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooledpost hocanalysis

Published:2017-09-08 Issue:12 Volume:30 Page:1275-1283
ISSN:0934-0874
Container-title:Transplant International
language:en
Short-container-title:Transpl Int

Author:

Legendre Christophe M.¹^ORCID,Campistol Josep M.²,Feldkamp Thorsten³,Remuzzi Giuseppe⁴⁵,Kincaid John F.⁶,Lommelé Åsa⁷,Wang Jimmy⁸,Weekers Laurent E.⁹,Sheerin Neil S.¹⁰

Affiliation:

1. Adult Kidney Transplant Unit; Université Paris Descartes and Hôpital Necker; Paris France

2. Renal Transplant Unit; Nephrology and Urology Department; Hospital Clinic; University of Barcelona; Barcelona Spain

3. Department of Nephrology and Hypertension; University Hospital Schleswig-Holstein; Christian Albrechts University Kiel; Kiel Germany

4. Unit of Nephrology; Division of Nephrology and Dialysis; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri; Centro Anna Maria Astori; Azienda Ospedaliera Ospedale Papa Giovanni XXIII; Bergamo Italy

5. Department of Biomedical and Clinical Science; L. Sacco; University of Milan; Milan Italy

6. Global Medical Affairs; Alexion Pharmaceuticals, Inc.; New Haven CT USA

7. Medical & Scientific Communication; Alexion Pharma GmbH; Zürich Switzerland

8. Biostatistics; Alexion Pharmaceuticals, Inc.; New Haven CT USA

9. Service of Nephrology, Dialysis and Transplantation; Centre Hospitalier Universitaire de Liège; Liège Belgium

10. Institute of Cellular Medicine; Newcastle University; Newcastle upon Tyne UK

Funder

Alexion Pharmaceuticals

CSL Behring

Astellas Pharma US

Pfizer

GlaxoSmithKline